BIOAF (Bioasis Technologies) Ending Cash Position: $0.12 Mil (As of Nov. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOAF Bioasis Technologies Inc BIOAF
12 GF Score
Price $0.00
View Full Analysis

What is Bioasis Technologies Ending Cash Position?

Bioasis Technologies BIOAF 12 Ending Cash Position is $0.12 Mil as of Nov. 2022. GuruFocus rates BIOAF with a GF Score™ of 12/100.

Bioasis Technologies's Ending Cash Position for the quarter that ended in Nov. 2022 was $0.12 Mil.

Bioasis Technologies's quarterly Ending Cash Position declined from May. 2022 ($0.60 Mil) to Aug. 2022 ($0.44 Mil) and declined from Aug. 2022 ($0.44 Mil) to Nov. 2022 ($0.12 Mil).

Bioasis Technologies's annual Ending Cash Position increased from Feb. 2020 ($0.43 Mil) to Feb. 2021 ($2.16 Mil) but then declined from Feb. 2021 ($2.16 Mil) to Feb. 2022 ($1.36 Mil).

Bioasis Technologies Ending Cash Position Related Terms

Bioasis Technologies Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Bioasis Technologies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Ending Cash Position Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 1.03 0.43 2.16 1.36

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 1.36 0.60 0.44 0.12
BIOAF
12GF Score
Bioasis Technologies Inc BIOAF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioasis Technologies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bioasis Technologies's Ending Cash Position for the fiscal year that ended in Feb. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.154+-0.792
=1.36

Bioasis Technologies's Ending Cash Position for the quarter that ended in Nov. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.422+-0.305
=0.12

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.12 Mil mean?
Bioasis Technologies (BIOAF) has a Ending Cash Position of $0.12 Mil as of Nov. 2022. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bioasis Technologies and its competitors.
Is Bioasis Technologies' Ending Cash Position too high?
Bioasis Technologies' current Ending Cash Position is $0.12 Mil. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' Ending Cash Position compare to VRTX and REGN?
Bioasis Technologies' Ending Cash Position of $0.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bioasis Technologies and its competitors. Bioasis Technologies's current Ending Cash Position is $0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current Ending Cash Position of $0.12 Mil. The current Ending Cash Position is $0.12 Mil. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current Ending Cash Position is $0.12 Mil as of Nov. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioasis Technologies Business Description

Address 157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score

Get the complete analysis for BIOAF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price